AI Article Synopsis
- Distinguishing inflammatory arthritis as an immune-related side effect in cancer patients is difficult due to similar musculoskeletal symptoms caused by their condition.
- Immune checkpoint inhibitors can worsen existing joint issues (like crystal-induced arthritis or osteoarthritis) and can also trigger systemic diseases that affect the joints, such as sarcoidosis.
- It's crucial to differentiate between these conditions, as their treatment approaches vary significantly from those for immune-related inflammatory arthritis.
Article Abstract
The differential diagnosis of inflammatory arthritis as an immune-related adverse event can be challenging as patients with cancer can present with musculoskeletal symptoms that can mimic arthritis because of localized or generalized joint pain. In addition, immune checkpoint inhibitors can exacerbate joint conditions such as crystal-induced arthritis or osteoarthritis, or induce systemic disease that can affect the joints such as sarcoidosis. This distinction is important as the treatment of these conditions can be different from that of immune-related inflammatory arthritis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rdc.2024.01.002 | DOI Listing |
Publication Analysis
Top Keywords
inflammatory arthritis
12
immune checkpoint
8
arthritis
5
mimickers immune
4
checkpoint inhibitor-induced
4
inhibitor-induced inflammatory
4
arthritis differential
4
differential diagnosis
4
diagnosis inflammatory
4
arthritis immune-related
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!